According to the latest research report the transarterial chemoembolization (TACE) market is projected to reach USD 15.61 Billion by 2030 at 4.90% CAGR during the forecast period 2022-2030.

Transarterial chemoembolization market is the current standard of therapy for patients with intermediate-stage hepatocellular carcinoma (HCC). Conventional TACE is considered as a standard treatment for HCC.